{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-277165","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.555505+00:00","generated_at":"2026-06-08T03:55:47.035961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Taysha Q3 net loss $117.1M on warrant expense; TSHA-102 well-tolerated with clinical improvements","bullets":["Net loss $117.1M ($0.93/shr) includes $100.5M non-cash fair value change in warrant liability; prior year net loss $26.5M.","Cash and cash equivalents $164.3M; runway extended into 2026 via new loan with Trinity Capital (no financial covenants or warrants).","TSHA-102 first two adult patients: well-tolerated, no SAEs; sustained improvements in autonomic, motor, socialization functions at week 12 (patient 1) and week 4 (patient 2).","IDMC cleared dosing of third adult patient; low-dose cohort completion and first U.S. pediatric dosing expected Q1 2024.","R&D expenses $11.8M (down from $16.8M YoY) due to lower headcount and licensing fees, partially offset by clinical trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-277165","json":"https://secwatch.observer/filing/0001193125-23-277165.json","markdown":"https://secwatch.observer/filing/0001193125-23-277165.md","text":"https://secwatch.observer/filing/0001193125-23-277165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523277165/0001193125-23-277165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523277165/d361794d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:55:47.035961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0a4eceb4ac0bf4c9133725e857b3d385bf997a1c","claim":"Taysha Gene Therapies, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 14, 2023, Taysha Gene Therapies, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended September 30, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523277165/0001193125-23-277165-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}